The product is used to treat patients with advanced squamous non-small cell lung cancer after prior therapy. The agency also granted priority review for this biologics licensing application and has given the Prescription Drug User Fee Act goal date of 22 June 2015, for a decision.
The FDA acceptance is based on data from CheckMate -063, a Phase II single arm, open-label trial designed to assess advanced squamous non-small cell lung cancer patients who progressed after both platinum-based therapy and at least one additional systemic therapy.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia